PHAIT, which stands for Prevention Health and Interception Therapeutics, is a pharma company that aims to intercept lung cancer by stopping the progression of pre-cancer dysplasia with the drug oral Iloprost. There has already been a successful Phase 2a clinical study where former smoker patients treated with oral Iloprost demonstrated a 50% reduction in pre-cancer endobronchial dysplasia, demonstrating the promise of lung cancer interception.
